{
  "id": "clinical#screening_cues_bd366d64",
  "content": "“unknown substance” should be used.\nThe name of the disorder is followed by the specification of onset\n(i.e., onset during intoxication, onset during discontinuation/with-\ndrawal), followed by the subtype designation (i.e., insomnia type,\ndaytime sleepiness type, parasomnia type, mixed type). Unlike the\nrecording procedures for ICD-10-CM, which combine the substance-\ninduced disorder and substance use disorder into a single code, for\nICD-9-CM a separate diagnostic code is given for the substance use\ndisorder. For example, in the case of insomnia occurring during with-\ndrawal in a man with a severe lorazepam use disorder, the diagnosis\nis 292.85 lorazepam-induced sleep disorder, with onset during with-\ndrawal, insomnia type. An additional diagnosis of 304.10 severe lo-\nrazepam use disorder is also given. When more than one substance is\njudged to play a significant role in the development of the sleep dis-\nturbance, each should be listed separately (e.g., 292.85 alcohol-in-\nduced sleep disorder, with onset during intoxication, insomnia type;\n292.85 cocaine-induced sleep disorder, with onset during intoxica-\ntion, insomnia type).\nICD-10-CM. The name of the substance/medication-induced sleep\ndisorder begins with the specific substance (e.g., cocaine, bupropion)\nOther Specified Insomnia Disorder 197\nthat is presumed to be causing the sleep disturbance. The diagnostic",
  "metadata": {
    "source": "DSM-5",
    "url": "https://psychiatry.org/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "sleep",
      "study",
      "screening_cues",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Screening Cues “unknown substance” should be used.\nThe name of the disorder is followed by the specification of onset\n(i.e., onset during intoxication, onset during discontinuation/with-\ndrawal), followed by the subtype designation (i.e., insomnia type,\ndaytime sleepiness type, parasomnia type, mixed type). Unlike the\nrecording procedures for ICD-10-CM, which combine the substance-\ninduced disorder and substance use disorder into a single code, for\nICD-9-CM a separate diagnostic code is given for the substance use\ndisorder. For example, in the case of insomnia occurring during with-\ndrawal in a man with a severe lorazepam use disorder, the diagnosis\nis 292.85 lorazepam-induced sleep disorder, with onset during with-\ndrawal, insomnia type. An additional diagnosis of 304.10 severe lo-\nrazepam use disorder is also given. When more than one substance is\njudged to play a significant role in the development of the sleep dis-\nturbance, each should be listed separately (e.g., 292.85 alcohol-in-\nduced sleep disorder, with onset during intoxication, insomnia type;\n292.85 cocaine-induced sleep disorder, with onset during intoxica-\ntion, insomnia type).\nICD-10-CM. The name of the substance/medication-induced sleep\ndisorder begins with the specific substance (e.g., cocaine, bupropion)\nOther Specified Insomnia Disorder 197\nthat is presumed to be causing the sleep disturbance. The diagnostic “unknown substance” should be used. the name of the disorder is followed by the specification of onset\n(i.e., onset during intoxication, onset during discontinuation/with-\ndrawal), followed by the subtype designation (i...."
}